JANX supply chain intelligence for Janux Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Janux Therapeutics, Inc. (JANX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MRK | Merck & Co., Inc. | 90% | Merck has the unilateral right to terminate the agreement in its entirety or on a Collaboration Target by Collaboration Target basis at any time and for any reason upon prior written notice to us. |
| MRK | Merck & Co., Inc. | 90% | Reciprocal relationship from MRK graph: Reciprocal relationship from JANX graph: Merck has the unilateral right to terminate the agreement in its entirety or on a Collaboration Target by Collaboratio… |
| WUXI-BIOLOGICS-HONG-KONG-LIMITED | WUXI-BIOLOGICS-HONG-KONG-LIMITED | 85% | In consideration for the license, we agreed to pay WuXi Biologics a non-refundable, one-time license fee of $0.2 million upon Wuxi Biologics’ achievement of a certain technical milestone, which was a… |
| BMY | Bristol-Myers Squibb Company | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks fo… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks … |
| BMYMP | Bristol-Myers Squibb Co | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| JNJ | Johnson & Johnson | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks fo… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks … |
| SNYNF | Sanofi | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| TLX | Telix Pharmaceuticals Limited | 72% | Reciprocal relationship from TLX graph: Reciprocal relationship from JANX graph: Reciprocal relationship from TLX graph: Reciprocal relationship from JANX graph: Reciprocal relationship from TLX grap… |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substant… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 92% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| BMY | Bristol-Myers Squibb Company | 92% | Reciprocal relationship from BMY graph: Reciprocal relationship from JANX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from JANX graph: Reciprocal relationship from BMY grap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from JANX graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from JANX graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| JNJ | Johnson & Johnson | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from JANX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from JANX graph: Reciprocal relationship from JNJ grap… |
| MYGN | Myriad Genetics, Inc. | 72% | that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringe… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from JANX graph: that issued patents will afford sufficient protection of our product candidates or their intended uses against compet… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks … |
| SNYNF | Sanofi | 72% | ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is possib… |
| ADAG | Adagene Inc. | 62% | Reciprocal relationship from ADAG graph: Reciprocal relationship from JANX graph: Reciprocal relationship from ADAG graph: Reciprocal relationship from JANX graph: Reciprocal relationship from ADAG g… |
| ADAGENE-BIOATLA-CHUGAI-PHARMACEUTICAL-CO-ROCHE-H | ADAGENE-BIOATLA-CHUGAI-PHARMACEUTICAL-CO-ROCHE-H | 62% | ons. Each master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the course of product development. It is … |
| BAC | Bank of America Corporation | 62% | Reciprocal relationship from BAC graph: Reciprocal relationship from JANX graph: per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares): As of March 31… |
| BOFA-SECURITIES-INC | BOFA-SECURITIES-INC | 62% | per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares): As of March 31, 2026 2025 Common stock options outstanding 10,386,109 9,995,064 Unvested RSUs 1… |
| HEALTH-RESOURCES | HEALTH-RESOURCES | 62% | val by the physician’s or health care professional’s employer, their competent professional organization and/or the regulatory authorities of the individual European Union member states. Failure to c… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| JANX-DEBT | Debt stack $21.6M | 90% | Market cache reports total debt of $21.6M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| JANX-OWNER-RA-CAPITAL-MANAGEMENT-L-P | RA CAPITAL MANAGEMENT, L.P. | 90% | 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 193 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 |